Cat:GMP-h-CYFRA21-1
Awaiting product image
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-CYFRA21-1 Categories , Tag

For more than 100mg, click here for inquiry. >>

Product Details

Genemedi produces core diagnostic ingredients for test of Cancer (bronchopulmonary dysplasia) and related syndrome. GeneMedi offers paired diagnostics grade soluble fragment of cytokeratin-19 (CYFRA21-1) antibodies (monoclonal antibody, mab) and antigens for Cancer (bronchopulmonary dysplasia) rapid test kit of soluble fragment of cytokeratin-19 (CYFRA21-1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Cancer (bronchopulmonary dysplasia ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.CYRFA 21-1 (cytokeratin 19 fragment) has been demonstrated as clinically useful in the prognostication and monitoring of non-small cell lung cancer (NSCLC). Elevated pretreatment levels may be associated with unfavorable prognosis, and decreasing levels during therapy predict an objective response to treatment. CYFRA 21–1 is a cytoplasmic protein fragment of cytokeratin 19 (CK-19) which is found in various epithelial malignancies, such as lung cancer[, gastrointestinal cancer and cervical cancer. This soluble debris can be released into the blood after tumor cell death, thus exhibiting a close relationship with tumor cell necrosis. Its level could be a proper indicator of necrosis degree. It has been reported that CYFRA 21–1 is a potential tumor marker for the diagnosis and prognosis of non-small cell lung cancer (NSCLC) and squamous carcinoma of the head and neck. Other studies have confirmed that the serum CYFRA 21–1 level before treatment is related to poor prognosis in patients with non-metastatic head and neck cancer(HNC).

Product Description

Cat No. of Pruducts

GMP-h-CYFRA21-1-Ag01:Recombinant Human CYFRA21-1 Protein

Product Name

Recombinant Human CYFRA21-1 Protein

Target

soluble fragment of cytokeratin-19

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

soluble fragment of cytokeratin-19 (CYFRA21-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYFRA21-1 level test of Cancer (bronchopulmonary dysplasia) and related syndrome evaluation

Tag

His

Products description

Recombinant Human CYFRA21-1 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-CYFRA21-1-Ab01,GMP-h-CYFRA21-1-Ab02:Anti-Human CYFRA21-1 mouse monoclonal antibody (mAb)

Product Name

Anti-Human CYFRA21-1 mouse monoclonal antibody (mAb)

Target

soluble fragment of cytokeratin-19 (CYFRA21-1)

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human soluble fragment of cytokeratin-19 (CYFRA21-1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble fragment of cytokeratin-19 (CYFRA21-1) antibodies in CYFRA21-1 level test of Cancer (bronchopulmonary dysplasia) and related syndrome evaluation.

Tag

mFc

Products description

Anti-Human CYFRA21-1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble fragment of cytokeratin-19 (CYFRA21-1) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.